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Introduction
In 1980, Mirowski et al. [1] reported the first 
3 patients treated with an automatic implantable 
defibrillator (AID). At that time, the AID was im-
planted with electrodes attached to the epicardium 
through a surgical thoracotomy with the battery 
portion of the unit placed undeer the skin in the 
abdominal wall. The AID detected the onset of 
ventricular fibrillation through a unique algorit-
hm and the device was considered a “shock box” 
since shock was the only therapy delivered. The 
U.S. Food and Drug Administration (FDA) initially 
provided approval for use of the AID device in high-
-risk cardiac patients who had been resuscitated 
from a prior aborted cardiac arrest.
Around the same time frame, Medtronic de-
veloped a pacing approach (antitachycardia pacing 
[ATP]) to terminate rapid ventricular tachycardia 
(VT) by delivering a series of appropriately timed 
pacing stimuli in the interval between the QRS 
and T-wave complexes of the tachycardia (review 
article [2]). This pacing technique was effective 
in terminating VT in a majority of patients with 
ventricular tachyarrhythmias. However, this ATP 
approach produced acceleration of VT and even 
ventricular fibrillation and sudden death in a small 
percentage of patients, and ATP therapy was not 
approved by the FDA as a stand-alone therapy.
The AID was initially developed by Drs. 
Mirowski and Mower in association with Dr. 
M. Stephen Heilman at the Medrad/Intec Company 
in Pittsburgh, Pennsylvania, and the implantable 
defibrillator was subsequently sold to CPI/Guidant 
Corporation in 1985. Although CPI/Guidant and 
Medtronic were competitors in the pacemaker 
field, both companies recognized the need for 
a device with tiered therapy that would include 
ATP and defibrillation. Through a  cooperative 
agreement, CPI/Guidant and Medtronic jointly 
agreed on a device involving ATP and shock the-
rapy, called the automatic implantable cardioverter 
defibrillator (AICD) for treating patients at risk for 
life-threatening VT and/or ventricular fibrillation. 
The first MADIT trial
Although the AICD was effective in termina-
ting ventricular tachyarrhythmias, it was unclear 
how effective it really was in saving lives in the 
absence of a randomized clinical trial. This point 
was driven home by the Cardiac Arrhythmia Sup-
pression Trial (CAST) that was initially reported 
in abstract form in 1989 [3] and published in 1991 
[4]. This randomized trial included a number of 
antiarrhythmic drugs including flecainide and en-
cainide that previously were shown to suppress 
ventricular ectopic beats. In the randomized an-
tiarrhythmic drug trial, these medications were 
associated with an increased mortality when com-
pared to conventional medical management, and 
the trial was stopped prematurely [4]. On the basis 
of the CAST trial, our multicenter group proposed 
to CPI/Guidant Corporation a randomized defibril-
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lator trial comparing the AICD to conventional 
drug therapy. The trial, called the Multicenter Au-
tomatic Defibrillator Implantation Trial (MADIT), 
was initiated in 1990 and involved 196 high-risk 
coronary patients with an ejection fraction £ 30%, 
documented asymptomatic non-sustained VT, and 
inducible, sustained, nonsuppressible ventricular 
tachyarrhythmia on electrophysiologic testing. 
These stringent, high-risk enrollment criteria were 
utilized since the AICD required a surgical thora-
cotomy and the randomized control group received 
conventional medical therapy and no thoracotomy. 
The results of this trial were reported in 1996 with 
a 54% reduction in mortality when comparing the 
AICD to conventional therapy (hazard ratio [HR] 
0.46, p = 0.009) [5]. The publication of this MADIT 
trial ushered in the AICD era.
MADIT-II
The implantation of the AICD using transve-
nous electrodes became available in 1994, and we 
initiated the MADIT-II trial in 1997 to evaluate the 
survival benefit of prophylactic transvenous AICD 
in 1232 patients with a prior myocardial infarction 
and a  left ventricular ejection fraction (LVEF) 
£ 30%. Patients were excluded from enrollment 
if they had coronary revascularization within the 
past 3 months or an acute myocardial infarction in 
the past month. This MADIT-II study, published 
in 2002, was associated with a 31% reduction in 
the risk of death in the AICD-treated patients as 
compared with patients in the conventional-therapy 
group (HR 0.69, p = 0.016) [6]. Secondary analyses 
revealed that patients who experienced overt heart 
failure (HF) during the clinical trial were at the 
greatest risk for developing life-threatening ven-
tricular tachyarrhythmias and achieved a greater 
benefit from the AICD [7]. 
MADIT-CRT
Since HF contributed significantly to the 
risk of arrhythmic events, our MADIT Executive 
Committee decided to try and reduce the likelihood 
of developing HF with cardiac resynchronization 
therapy (CRT) in cardiac patients with mild-to-
-moderate HF. The randomized MADIT-CRT trial 
began in January 2003 and enrolled 1820 patients 
with NYHA Class I or II HF, LVEF £ 30%, and 
a QRS duration of ³ 130 ms. MADIT-CRT was 
published in 2009 [8]. During an average follow-up 
of 2.4 years, CRT-D therapy was associated with 
a 34% reduction in death or HF, whichever came 
first, as compared to patients receiving implan-
table cardioverter-defibrillator (ICD)-only therapy 
(HR 0.66, p = 0.001). The benefit associated with 
CRT-D was dominated by the reduction in HF events.
MADIT-RIT
During the aforementioned MADIT trials 
and in a spectrum of device studies by other inve-
stigators, it was noted that inappropriate ICD or 
CRT-D therapies were frequent, with the potential 
for adverse effects. The definition of inappropriate 
therapy refers to ATP or shock therapy delivered 
for atrial tachyarrhythmias rather than for ven-
tricular tachyarrhythmias. Beginning in 2009, we 
enrolled 1500 patients with a primary-prevention 
indication to receive an ICD or CRT-D devices with 
randomization to one of 3 programming configura-
tions to determine which programming approach 
was most effective in reducing inappropriate 
therapy. This trial called MADIT-Reduce Inappro-
priate Therapy (MADIT-RIT) was published in 
2012 and showed that device programming for 
therapy at a high tachycardia rate (³ 200 bpm) 
was associated with a significant 79% reduction 
in first occurrence of inappropriate therapy and 
a significant 55% reduction in death as compared 
to conventional programming group with therapy 
beginning at 170 bpm with 2.5 s delay [9]. Similar 
but less significant findings were observed when 
comparing inappropriate therapy in the delayed 
therapy group (60 s delay before firing at 170 bpm) 
to the conventional therapy group. In the overall 
trial, the improved programming was associated 
with a 6 to 8-fold reduction in inappropriate ATP 
and a 2 to 4-fold reduction in inappropriate shock 
therapy. More specifically, the total inappropriate 
shock energy delivered during the course of the 
trial was 3,714 joules in the conventional thera-
py group, 868 joules in the high-rate group, and 
1,698 joules in the delayed therapy group.
Clinical implications of MADIT-RIT
The clinical implications of the MADIT-RIT 
trial are that inappropriate ATP delivered for atrial 
tachycardias and unnecessary shock therapy for 
VTs in the 170 to 199 bpm range are risky, and 
elimination of these therapies is associated with 
reduced mortality. Clearly, the existing device 
algorithms for distinguishing between supra-
ventricular tachycardia (sinus tachycardia, atrial 
tachyarrhythmias, atrial flutter/fibrillation) and 
ventricular tachyarrhythmias do not work well. In 
addition, ATP and shock therapy for non-sustained 
VT in the 170–199 bpm range is not needed and 
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can be considered unnecessary. It should be em-
phasized that this improved programming that was 
demonstrated in MADIT-RIT reduced mortality 
by 55% on top of the previously documented 31% 
reduction in mortality in ICD-treated patients that 
was shown in MADIT-II [6]. This improved ICD 
programming is already being accepted by leaders 
in field [10].
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